Helen M. Heneghan

Helen M. Heneghan

Auto-generated profile, based on publicly available information

Helen M. Heneghan

Department of Upper GI and Bariatric Surgery, St Vincent’s University Hospital, Dublin 4, Ireland

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Annals of Surgery
Verified
Journal Article
Closed access
VFVictor Warren Md Fazio
Victor Warren Md Fazio
RKRavi P. Md Kiran
Ravi P. Md Kiran
FRFeza H. Md Remzi
Feza H. Md Remzi
JCJohn Calvin PhD Coffey
John Calvin PhD Coffey
HHHelen Mary PhD Heneghan
Helen Mary PhD Heneghan
SMSean T. Md Martin
Sean T. Md Martin
Background: Ileal pouch anal anastomosis (IPAA) is the treatment of choice for chronic, medically refractory mucosal ulcerative colitis, indeterminate colitis, familial adenomatous polyposis (FAP), and a select group of patients with Crohn's disease. Aim: We report outcomes, complications, and quality of life (QOL) in a cohort of 3707 patients treated at our institution from January 1984 to March 2010. Methods: Data were collected from a prospectively maintained database and chart review of 3707 consecutive primary IPAA cases. Patient demographics, postoperative complications, functional outcomes, and QOL data were available. Follow-up consisted of clinical examination with assessment of pouch function and QOL. Results: A total of 3707 patients underwent primary pouch and 328 underwent redo pouch surgery. Postoperative histopathological diagnoses were mucosal ulcerative colitis (n = 2953, 79.7%), indeterminate colitis (n = 63, 1.7%), FAP (n = 223, 6%), Crohn's disease (n = 150, 4%), cancer/dysplasia (n = 97, 2.6%), and others (n = 221, 6.0%). Early perioperative complications were encountered in 33.5% of patients with a mortality rate of 0.1%. Excluding pouchitis, late complications were experienced by 29.1% of patients. Of those patients who had IPAA at our institution, pouch failure occurred in 197 patients (5.3%). During a median follow-up of 84 months, 119 patients (3.2%) required excision of the pouch, 32 (0.8%) had a nonfunctioning pouch, and 46 patients (1.2%) had redo IPAA. Functional outcomes and QOL were good or excellent in 95% of patients and similar in each histopathological subgroup. Conclusions: IPAA is an excellent option for patients with MUC, IC, FAP, and select patients with Crohn's disease.

1 March 2010 in Annals of Surgery
Verified
Journal Article
Closed access
HHHelen M. Heneghan
Helen M. Heneghan
NMNicola Miller
Nicola Miller
ALAoife J Lowery
Aoife J Lowery
KSKarl J. Sweeney
Karl J. Sweeney
JNJohn Newell
John Newell
MKMichael J. Kerin
Michael J. Kerin
Objective: The development of clinically validated biomarkers for cancer has remained an insurmountable task despite other advances in the field of cancer molecular biology. Mi(cro)RNAs have many characteristics of an ideal biomarker most notably their inherent stability and resilience. Recent blood-based miRNA profiling studies, reporting their presence in serum and plasma, have generated the concept that circulating miRNAs hold much potential as novel noninvasive biomarkers for cancer and other disease processes. The objective of this study was to investigate the potential of circulating microRNAs as novel breast cancer biomarkers. Methods: Using a novel approach to extract miRNAs from the circulation followed by real-time quantitative polymerase chain reaction analysis, levels of a panel of 7 candidate miRNAs were quantified in tissue and blood specimens of 148 patients with breast cancer and 44 age-matched and disease free control individuals. Results: We report that cancer-specific miRNAs were detected and significantly altered in the circulation of breast cancer patients, and that increased systemic miR-195 levels in breast cancer patients were reflected in breast tumors. Furthermore, we identified that circulating levels of miR-195 and let-7a decreased in cancer patients postoperatively, to levels comparable with control subjects, following curative tumor resection. Finally, we found that specific circulating miRNAs correlated with certain clinicopathological variables, namely nodal status and estrogen receptor status. Conclusion: These findings suggest that systemic miRNAs have potential use as novel breast cancer biomarkers and may prove useful in clinical management during the perioperative period.

23 February 2012 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
SMS. T. Martin
S. T. Martin
HHH. M. Heneghan
H. M. Heneghan
DWD. C. Winter
D. C. Winter

17 October 2012 in Heart
Verified
Journal Article
Closed access
PDF file
AVAmanda R Vest
Amanda R Vest
HHHelen M Heneghan
Helen M Heneghan
SAShikhar Agarwal
Shikhar Agarwal
PSPhilip R Schauer
Philip R Schauer
JYJames B Young
James B Young
Purpose To quantify the impact of bariatric surgery on cardiovascular (CV) risk factors, and on cardiac structure and function. Data sources Three major databases (PubMed, Medline and Cochrane) were searched for original studies written in English. Study selection Original articles reporting CV risk factors or non-invasive imaging parameters for patients undergoing bariatric surgery, from January 1950 to June 2012. Data extraction Data extraction from selected studies was based on protocol-defined criteria that included study design, methods, patient characteristics, surgical procedures, weight loss, changes in CV risk factors, cardiac structure and cardiac function postoperatively. Data synthesis 73 CV risk factor studies involving 19 543 subjects were included (mean age 42 years, 76% female). Baseline prevalence of hypertension, diabetes and hyperlipidaemia were 44%, 24%, and 44%, respectively. Mean follow-up was 57.8 months (range 3–176) and average excess weight loss was 54% (range 16–87%). Postoperative resolution/improvement of hypertension occurred in 63% of subjects, of diabetes in 73% and of hyperlipidaemia in 65%. Echocardiographic data from 713 subjects demonstrated statistically significant improvements in left ventricular mass, E/A ratio, and isovolumic relaxation time postoperatively. Limitations Diagnostic criteria, CV risk factor reporting, and imaging parameters were not uniform across all studies. Study groups were heterogeneous in their demographics, operative technique and follow-up period. Conclusions This systematic review highlights the benefits of bariatric surgery in reducing risk factors for CV disease. There is also evidence for left ventricular hypertrophy regression and improved diastolic function. These observations provide further evidence that bariatric surgery enhances future CV health for obese individuals.

24 June 2010 in The Oncologist
Verified
Journal Article
Open access
PDF file
HHHelen M. Heneghan
Helen M. Heneghan
NMNicola Miller
Nicola Miller
RKRonan Kelly
Ronan Kelly
JNJohn Newell
John Newell
MKMichael J. Kerin
Michael J. Kerin
Learning Objectives: After completing this course, the reader will be able to: Describe the site-specific dysregulation of some miRNAs and explain their potential as non-invasive biomarkers for diagnosis, prognostication, or markers of treatment response.Cite the characteristics reflected by circulating miR-195 and explain how elevated levels could be used as a breast tumor marker. CME This article is available for continuing medical education credit at CME.TheOncologist.com Purpose.: The potential of microRNAs (miRNAs) as novel tumor markers has been the focus of recent scrutiny because of their tissue specificity, stability, and association with clinicopathological parameters. Data have emerged documenting altered systemic miRNA expression across a spectrum of cancers; however, it remains uncertain as to whether circulating miRNAs are tumor specific. Our aim was to assess a panel of cancer-associated miRNAs in the circulation of patients with various malignancies, to determine whether these “oncomirs” were tumor specific, and thus to establish whether systemic miRNA analysis has utility in cancer diagnosis. Patients and Methods.: Whole blood samples were prospectively collected from preoperative cancer patients (breast, prostate, colon, and renal cancer and melanoma; n = 163) and healthy age- and sex-matched controls (n = 63). Total RNA was isolated, and a panel of seven miRNAs was quantified by real-time quantitative polymerase chain reaction in each sample. Results.: Differential expression of the general oncomirs let 7a, miR-10b, and miR-155, was observed in the majority of cancer patients in a nonspecific manner. Significantly, elevated circulating miR-195 was found to be breast cancer specific and could differentiate breast cancer from other cancers and from controls with a sensitivity of 88% at a specificity of 91%. A combination of three circulating miRNAs, including miR-195, further enhanced the discriminative power of this test for breast cancer to 94%. Conclusion.: These findings suggest that individual cancers display specific systemic miRNA profiles, which could aid in discriminating among cancer types. This finding is of notable clinical consequence because it illustrates the potential of systemic miRNAs as sensitive, specific, noninvasive cancer biomarkers.

1 October 2010 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
HHHelen M Heneghan
Helen M Heneghan
NMNicola Miller
Nicola Miller
MKMichael J. Kerin
Michael J. Kerin